Hot flush – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:03:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hot flush – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Relative bioavailability and safety of elinzanetant soft‑gel capsules in healthy adults for vasomotor symptoms https://clinicaltrials.eu/trial/relative-bioavailability-and-safety-of-elinzanetant-soft-gel-capsules-in-healthy-adults-for-vasomotor-symptoms/ Fri, 05 Jun 2026 04:02:49 +0000 https://clinicaltrials.eu/trial/relative-bioavailability-and-safety-of-elinzanetant-soft-gel-capsules-in-healthy-adults-for-vasomotor-symptoms/ The study looks at a condition called vasomotor symptoms, which are hot flashes and night sweats that can happen when sex hormones change in women and men. The medication being examined is an oral pill that contains the active ingredient elinzanetant, also known by its code name BAY 3427080, and it is provided in a soft gel capsule form.

The purpose of the study is to compare how much of the medication is absorbed into the bloodstream from different capsule formulations. Participants will take a single dose of each capsule type while fasting, meaning they will not eat for several hours before taking the medicine, and the study will follow a simple schedule where each dose is given at separate times.

Researchers will watch for any adverse events, which are side effects or unwanted reactions, and will record how often they occur and how severe they are, while also measuring how much of the drug reaches the blood to understand its bioavailability.

]]> Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy https://clinicaltrials.eu/trial/study-on-fezolinetant-for-reducing-hot-flashes-in-women-with-hormone-receptor-positive-breast-cancer-on-hormone-therapy/ Wed, 29 Apr 2026 14:58:50 +0000 https://clinicaltrials.eu/trial/study-on-fezolinetant-for-reducing-hot-flashes-in-women-with-hormone-receptor-positive-breast-cancer-on-hormone-therapy/ This study focuses on women with hormone receptor-positive breast cancer who experience moderate to severe vasomotor symptoms (hot flashes) while receiving hormone therapy. These hot flashes can significantly impact daily life and occur as a side effect of breast cancer treatment. The study will test a medication called fezolinetant, which is being investigated to help reduce these symptoms.

The purpose of the study is to determine if fezolinetant 45 mg taken once daily can effectively reduce both the frequency and severity of hot flashes compared to placebo in women undergoing breast cancer hormone therapy. During the study, participants will take either fezolinetant as a film-coated tablet or a matching placebo tablet daily for up to 52 weeks.

The medication will be given to women who are currently receiving stable maintenance adjuvant endocrine therapy (hormone therapy) such as tamoxifen or aromatase inhibitors. Throughout the study, participants will need to record their hot flash symptoms in an electronic diary. The study will monitor how well the treatment works and any potential side effects that may occur.

]]> Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer https://clinicaltrials.eu/trial/study-on-elinzanetant-for-treating-hot-flashes-in-women-with-or-at-high-risk-for-hormone-receptor-positive-breast-cancer/ Wed, 29 Apr 2026 14:56:52 +0000 https://clinicaltrials.eu/trial/study-on-elinzanetant-for-treating-hot-flashes-in-women-with-or-at-high-risk-for-hormone-receptor-positive-breast-cancer/ This clinical trial is focused on studying the effectiveness and safety of a medication called elinzanetant for treating hot flashes in women who are either undergoing or at high risk for developing hormone-receptor positive breast cancer. Hot flashes are sudden feelings of warmth, often associated with sweating, that can be caused by certain cancer treatments known as adjuvant endocrine therapy. This study aims to see how well elinzanetant works in reducing these symptoms compared to a placebo, which is a substance with no active medication.

Participants in the study will be randomly assigned to receive either elinzanetant or a placebo. The study will last for 52 weeks, with an option to continue for an additional two years. During this time, participants will take the medication in the form of soft capsules by mouth. The study will monitor changes in the frequency and severity of hot flashes over time, as well as any effects on sleep and quality of life.

The goal of the study is to provide more information about how elinzanetant can help manage hot flashes in women affected by hormone-receptor positive breast cancer treatments. By comparing the results between those taking elinzanetant and those taking a placebo, researchers hope to better understand the potential benefits and safety of this treatment option.

]]>